Rare Disease Economics
The discussion highlights how the pricing model for rare diseases allows for higher returns during patent life, incentivizing research in areas that impact smaller patient populations. With a dedicated healthcare team managing approximately 65 to 70 billion in assets, the focus remains on long-term investment strategies, reflecting the unique dynamics of the biotech industry. The importance of understanding industry cycles and maintaining a broad perspective is emphasized as essential for effective portfolio management.In this clip
From this podcast
Capital Allocators – Inside the Institutional Investment Industry
[REPLAY] Jean Hynes – Inside Wellington Management (Capital Allocators, EP.82)
Related Questions